For mesothelioma, we found the same top altered genes as in the TCGA cohort, such as loss of CDKN2A or TP53, NF2 or BAP1 mutations, none of which have currently been linked to a possible treatment. This evidence concerns the gene CDKN2A and mesothelioma.